Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT01302808 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Metastatic Cancer

Interventions

COMBINATION_PRODUCT: Erlotinib plus Romidepsin (8 mg/m^2)
COMBINATION_PRODUCT: Erlotinib plus Romidepsin (10 mg/m^2)
COMBINATION_PRODUCT: Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
COMBINATION_PRODUCT: (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]
[object Object]